寡转移性前列腺癌患者接受转移灶导向立体定向体部放疗后CD8+ T细胞的前瞻性免疫表型分析及其相关临床结局
本研究前瞻性分析37例寡转移性前列腺癌(≤3个转移灶)患者接受转移灶导向立体定向体部放疗(mdSBRT)前后外周血CD8+ T细胞亚群变化。中位随访39个月,3年总生存率78.2%,局部进展和新区转移的3年累积发生率分别为16.5%和67.6%。基线至mdSBRT后第14天,中央记忆T细胞(TCM)亚群增加与死亡风险相关(HR 1.22,95%CI 1.02-1.47,P=0.033),肿瘤反应性T细胞(TTR)亚群增加对局部进展风险具有保护作用(HR 0.80,95%CI 0.65-0.98,P=0.032)。
要点
- 37例寡转移性前列腺癌患者接受mdSBRT,中位随访39个月,3年总生存率78.2%。
- 基线至第14天TTR细胞增加与局部进展风险降低相关(HR 0.80,95%CI 0.65-0.98)。
- 基线至第14天TCM细胞增加与死亡风险升高相关(HR 1.22,95%CI 1.02-1.47)。
核心结论
- TTR细胞亚群增加对疾病进展风险具有保护作用,TCM细胞亚群增加与死亡风险相关。
- 更好地理解CD8+ T细胞亚群并增强其抗肿瘤效应可能进一步改善疾病控制。
研究设计与样本
- 前瞻性研究,纳入37例寡转移性前列腺癌(≤3个转移灶)患者,接受转移灶导向立体定向体部放疗(mdSBRT)。
- 前瞻性分离外周血单核细胞,在mdSBRT前后进行免疫表型分析,识别循环CD8+ T细胞亚群,包括肿瘤反应性(TTR)、效应记忆、中央记忆(TCM)、效应和初始T细胞。
- 采用单因素Cox比例风险回归评估T细胞亚群变化是否为死亡和/或进展的潜在危险因素,Kaplan-Meier法用于生存分析,考虑死亡为竞争风险估计进展和新区转移的累积发生率。
主要发现
- 中位随访39个月(四分位距34-43),3年总生存率为78.2%。
- 3年局部进展累积发生率为16.5%,新区转移累积发生率为67.6%。
- 基线至mdSBRT后第14天,TCM细胞亚群增加与死亡风险相关(HR 1.22,95%CI 1.02-1.47;P=0.033)。
- 基线至mdSBRT后第14天,TTR细胞亚群增加对局部进展风险具有保护作用(HR 0.80,95%CI 0.65-0.98;P=0.032)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study examined the effects of metastasis-directed stereotactic body radiation therapy (mdSBRT) on CD8+ T-cell subpopulations and correlated post-mdSBRT immunophenotypic responses with clinical outcomes in patients with oligometastatic prostate cancer (OPCa). METHODS AND MATERIALS: Peripheral blood mononuclear cells were prospectively isolated from 37 patients with OPCa (≤3 metastases) who were treated with mdSBRT. Immunophenotyping identified circulating CD8+ T-cell subpopulations, including tumor-reactive (TTR), effector memory, central memory (TCM), effector, and naïve T cells from samples collected before and after mdSBRT. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and/or progression. The Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis weas estimated, considering death as a competing risk. RESULTS: Median follow-up was 39 months (interquartile range, 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression and new distant metastasis at 3 years was 16.5% and 67.6%, respectively. Between baseline and day 14 after mdSBRT, an increase in the TCM cell subpopulation was associated with the risk of death (hazard ratio, 1.22 [95% confidence interval, 1.02-1.47]; P = .033), and an increase in the TTR cell subpopulation was protective against the risk of local progression (hazard ratio, 0.80 [95% confidence interval, 0.65-0.98]; P = .032). CONCLUSIONS: An increase in the TTR cell subpopulation was protective against the risk of disease progression, and an increase in the TCM cell subpopulation was associated with the risk of death in patients with OPCa treated with mdSBRT. Disease control may be further improved by better understanding the CD8+ T-cell subpopulations and by enhancing their antitumor effect.
引用
- Evans JD, Morris LK, Zhang H, et al. Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. Int J Radiat Oncol Biol Phys. 2018. PMID: 30205124. doi:10.1016/j.ijrobp.2018.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。